Medical research
A team of researchers from McGill University has published a study on the effectiveness of a decision support system (DSS) in improving glycemic control in adults with type 1 diabetes. According to the study, the DSS, which consists of a mobile application and a titration algorithm, provides weekly basal and
Diseases
Lundbeck's pipeline developments for amlenetug, a novel investigational molecule for treating Multiple System Atrophy (MSA), will be presented at the 2025 International Congress of Parkinson's Disease and Movement Disorders in Honolulu, Hawaii. Amlenetug, a human monoclonal antibody, targets pathological aggregations of the protein a-synuclein in the
Medical research
A clinical trial has been registered in Australia to study the effectiveness of continuous glucose monitoring (CGM) and a culturally appropriate primary care pharmacist prescriber model of care in managing type 2 diabetes in Pacific adults. The trial, led by Prof Ben Wheeler, aims to investigate whether the use of
Cancer research
A new study has been conducted to examine the concordance among 26 next-generation sequencing (NGS) laboratories participating in the National Cancer Institute's (NCI) Molecular Analysis for Therapy Choice (NCI-MATCH) clinical trial. The study aimed to compare variant detection and reporting between a wide range of testing platforms. Funded
Cancer research
Haystack Oncology, a Quest Diagnostics company, has announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD, a highly sensitive ctDNA test, to help optimize postoperative therapy decisions in patients with stage II/III non-small cell lung cancer (NSCLC). The study, titled "Trial
Cancer research
Jonsson Comprehensive Cancer Center has listed an interventional clinical trial, Phase 2, to investigate the effectiveness of Eclipse: Flotufolastat F 18 in detecting residual or recurrent cancer after prostate focal therapy. The trial's principal investigator is Wayne Brisbane, and it is being conducted in collaboration with BLUE EARTH
Diseases
MapLight Therapeutics has initiated a Phase 2 study to evaluate the efficacy, safety, and tolerability of ML-007C-MA, an investigational novel M 1 /M 4 agonist, as a potential treatment for Alzheimer's disease psychosis (ADP). The study, known as VISTA, is a randomized, double-blind, placebo-controlled trial that aims to
Diseases
Researchers at Ludwig-Maximilians-University Munich have evaluated the distribution and risk of disease progression in first-line therapy of unresected metastatic colorectal cancer patients. The study analyzed data from 11 clinical trials to provide guidance for the timing of disease reassessments during first-line therapy. Key Takeaways: * The maximum frequency of disease progression
Diseases
CSPC Pharmaceutical Group Limited, a leading Chinese pharmaceutical company, has made significant progress in the development of ALMB-0166, a novel humanized monoclonal antibody inhibitor targeting Connexin 43 (Cx43). The company has announced that ALMB-0166 has obtained approval from the National Medical Products Administration of China to conduct a Phase II
Diseases
A recent study from Lebanese University has identified Mucuna pruriens, a plant traditionally used in Ayurvedic medicine, as a potential therapeutic option for managing symptoms of Parkinson's disease (PD). The systematic review, published in the journal Parkinson's Disease, investigated the efficacy and safety of Mucuna pruriens
Aflibercept
Research findings on the effectiveness of the biosimilar CT-P42 in treating diabetic macular edema have been discussed in a new report. A 24-week phase 3 analysis earlier demonstrated equivalent efficacy and comparable tolerability between CT-P42 and the reference aflibercept in participants with diabetic macular edema. The latest study reports long-term
Diseases
In a groundbreaking study published in Frontiers in Veterinary Science, researchers from VIP Animal Medical Center in Seoul, South Korea, have discovered a novel fixed-dose combination tablet, Sentorphil ForteGold, to be a clinically effective and safer alternative to traditional compounded powdered medications for managing myxomatous mitral valve disease (MMVD) in
